CD274 and non-small cell lung carcinoma: A recent network meta-analysis (NMA) evaluated the efficacy of the available anti-PD-L1-containing immunotherapy strategies in monotherapy for the first-line treatment of patients with high PD-L1 expression (≥50%) and locally advanced or metastatic NSCLC.